0001213900-23-089628.txt : 20231122 0001213900-23-089628.hdr.sgml : 20231122 20231122164814 ACCESSION NUMBER: 0001213900-23-089628 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Modular Medical, Inc. CENTRAL INDEX KEY: 0001074871 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870620495 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-264193 FILM NUMBER: 231434099 BUSINESS ADDRESS: STREET 1: 16772 WEST BERNARDO DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92127 BUSINESS PHONE: 858-800-3500 MAIL ADDRESS: STREET 1: 16772 WEST BERNARDO DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92127 FORMER COMPANY: FORMER CONFORMED NAME: BEAR LAKE RECREATION INC DATE OF NAME CHANGE: 19981208 424B5 1 ea188782-424b5_modular.htm PROSPECTUS SUPPLEMENT

As Filed Pursuant to Rule 424(b)(5)

Registration No. 333-264193

 

PROSPECTUS SUPPLEMENT

(To Prospectus dated April 19, 2022)

 

Up to $6,500,000

 

 

 

Common Stock

 

We have entered into a sales agreement with Leerink Partners LLC (“Leerink Partners”) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $6,500,000 from time to time through or to Leerink Partners, acting as agent or principal.

 

Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “MODD”. On November 21, 2023, the last reported sale price of our common stock on Nasdaq was $1.03 per share.

 

Sales of our common stock, if any, under this prospectus supplement will be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Leerink Partners is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Leerink Partners and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

 

The compensation to Leerink Partners for sales of common stock sold pursuant to the sales agreement will be an amount equal to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Leerink Partners will be deemed to be underwriting commissions or discounts. See “Plan of Distribution” beginning on page S-8  for additional information regarding the compensation to be paid to Leerink Partners. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

As of the date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates is $19,752,589, based on 21,227,226 shares of outstanding common stock, of which 15,553,220 shares are held by non-affiliates, and a per share price of $1.27, which was the closing sale price of our common stock as quoted on Nasdaq on October 31, 2023. As of the date of this prospectus supplement, we have not offered and sold any of our securities pursuant to General Instruction I.B.6. of Form S-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000.

 

We are a "smaller reporting company" under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus supplement and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See "Summary—Implications of Being a Smaller Reporting Company.”

 

Our business and an investment in our common stock involve significant risks. These risks are described under the caption “Risk Factors” beginning on page S-3 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.

 

Leerink Partners

 

November 22, 2023

 

 

 

 

TABLE OF CONTENTS 

 

ABOUT THIS PROSPECTUS   S-ii
PROSPECTUS SUMMARY   S-1
THE OFFERING   S-2
RISK FACTORS   S-3
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS   S-4
USE OF PROCEEDS   S-6
DILUTION   S-7
PLAN OF DISTRIBUTION   S-8
LEGAL MATTERS   S-9
EXPERTS   S-9
WHERE YOU CAN FIND MORE INFORMATION   S-9
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE   S-10

 

  Page
   
ABOUT THIS PROSPECTUS ii
PROSPECTUS SUMMARY 1
RISK FACTORS 2
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3
USE OF PROCEEDS 4
GENERAL DESCRIPTION OF SECURITIES 5
DESCRIPTION OF CAPITAL STOCK 6
DESCRIPTION OF DEBT SECURITIES 7
DESCRIPTION OF WARRANTS 9
DESCRIPTION OF UNITS 10
PLAN OF DISTRIBUTION 10
LEGAL MATTERS 12
EXPERTS 12
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 13
WHERE YOU CAN FIND MORE INFORMATION 13

 

S-i

 

 

ABOUT THIS PROSPECTUS

 

This prospectus is part of a shelf registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the “SEC”). Under the shelf registration process, we may sell or issue any of the combination of securities described in the accompanying base prospectus in one or more offerings with a maximum aggregate offering price of up to $50,000,000 from time to time, at prices and on terms to be determined by market conditions at the time of the offering.

 

We provide information to you about this offering of shares of our common stock in two separate documents that are bound together: (1) this at-the-market sales agreement prospectus supplement, which describes the specific details regarding this offering; and (2) the accompanying base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” we are referring to both the at-the-market sales agreement prospectus supplement and the accompanying base prospectus combined. If information in this at-the-market sales agreement prospectus supplement is inconsistent with the accompanying base prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date—for example, a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates.

 

You should rely only on the information contained in, or incorporated by reference into, this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Leerink Partners has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Leerink Partners is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled “Where You Can Find More Information” and “Incorporation by Reference.”

 

We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

 

In this prospectus, the terms “MODD,” “Modular Medical,” “Company,” “we,” “us,” “our” and similar terms refer to Modular Medical, Inc., a Nevada corporation, and its subsidiaries unless the context otherwise requires.

 

This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference in this prospectus are the property of their respective owners.  

 

S-ii

 

 

PROSPECTUS SUMMARY

 

This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in the securities covered by this prospectus. For a more complete understanding of MODD and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference in this prospectus and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information referred to under the heading “Risk Factors” in this prospectus beginning on page S-3. 

 

Overview

 

We are a development-stage medical device company focused on the design, development and commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

 

Implications of Being a Smaller Reporting Company

 

We are a “smaller reporting company” as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter.

 

Corporate Information

 

We are a Nevada corporation, and Quasuras, Inc., a Delaware corporation, is our only subsidiary. Our corporate headquarters and operating facilities are located at 10740 Thornmint Road, San Diego, CA 92127. Our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com. The information contained on or that can be accessed through our website is not incorporated by reference into this prospectus and you should not consider information on our website to be part of this prospectus or in deciding whether to purchase our securities.

 

S-1

 

 

The Offering

 

Common stock offered by us   Shares having an aggregate offering price of up to $6,500,000.
     
Common stock to be outstanding after this offering   Up to 27,537,905 shares, assuming the sale of $6,500,000 of shares at a sales price of $1.03 per share, which was the last reported sale price on Nasdaq on November 21, 2023. The actual number of shares issued and outstanding will vary depending on the sales price under this offering.
     
Manner of offering  

Sales of our common stock by Leerink Partners, if any, under this prospectus may be made by any method permitted by law and deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act, from time to time through or to Leerink Partners, as sales agent or principal. See “Plan of Distribution” on page S-8 of this prospectus.

     
Use of proceeds   Our management will retain broad discretion regarding the allocation and use of the net proceeds from this offering. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including working capital, to fund our operations through the approval of our product by the FDA, develop our initial sales and marketing infrastructure, to fund additional research and development activities, to expand our manufacturing and production capabilities and make related capital expenditures. See “Use of Proceeds” on page S-6 of this prospectus.
     
Nasdaq Capital Market symbol   “MODD”
     
Risk factors   Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-3 of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors that you should carefully consider before deciding to invest in shares of our common stock.

 

The number of shares of common stock shown above to be outstanding immediately following this offering is based on 21,227,226 shares outstanding as of November 21, 2023 and excludes:

 

767,796 shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.00 per share;

 

5,449,478 shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.60 per share;

 

604,623 shares of our common stock issuable upon the exercise of warrants with an exercise price of $1.32 per share;

 

4,966,217 shares of our common stock issuable upon the exercise of warrants with an exercise price of $1.22 per share;

 

1,348,314 shares of our common stock issuable upon exercise of pre-funded warrants with an exercise price of $0.01 per share;

 

3,711,407 shares of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately $3.69 per share;

 

229,166 shares of our common stock issuable upon vesting of restricted stock units; and

 

639,335 shares of our common stock reserved for issuance pursuant to future awards under our Amended and Restated 2017 Equity Incentive Plan, or the 2017 Plan.

 

This prospectus reflects and assumes no exercise of outstanding options or warrants.

 

S-2

 

 

RISK FACTORS

 

Investing in our securities involves risk. You should carefully consider the specific risks discussed below, together with all the other information contained in the prospectus or incorporated by reference into this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the caption “Risk Factors” included in our Annual Report on Form 10-K for the year ended March 31, 2023 and in our Quarterly Reports on Form 10-Q for the periods ended June 30, and September 30, 2023, and in subsequent filings, which are incorporated by reference into this prospectus, which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future that are incorporated by reference in this prospectus. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your investment.

 

Risks Related to This Offering

 

We have broad discretion in the use of the net proceeds from this offering.

 

Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways with which you may not agree. Accordingly, you will be relying on the judgment of our management with regard to the use of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested or otherwise used in a way that does not yield a favorable, or any, return for the Company.

 

Investors in this offering will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.

 

Since the price per share of our common stock being offered is higher than the net tangible book value per share of our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. See the section entitled “Dilution” in this prospectus for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. In addition, we have a significant number of options outstanding. If the holders of these options exercise such options, you may incur further dilution.

 

Our stockholders may experience significant dilution as a result of future equity offerings and exercise of outstanding options.

 

In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.

 

In addition, we have a number of securities allowing the purchase of, our common stock. As of November 21, 2023, 639,335 shares of common stock were reserved for future issuance under our 2017 Plan. As of that date, there were also equity awards and warrants outstanding of 3,940,573, and 13,136,428 shares of our common stock, respectively. The vesting of restricted stock units and exercise of outstanding options and warrants having an exercise price per share that is less than the offering price per share in this offering will increase dilution to investors in this offering.

 

It is not possible to predict the aggregate proceeds resulting from sales made under the sales agreement.

 

Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Leerink Partners at any time throughout the term of the sales agreement. The number of shares that are sold through Leerink Partners after delivering a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the sales period, any limits we may set with Leerink Partners in any applicable placement notice and the demand for our common stock. Because the price per share of each share sold pursuant to the sales agreement will fluctuate over time, it is not currently possible to predict the aggregate proceeds to be raised in connection with sales under the sales agreement.

 

The common stock offered hereby will be sold in “at the market offerings” and investors who buy shares at different times will likely pay different prices.

 

Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering. In addition, subject to the final determination by our board of directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.

 

S-3

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, which we refer to as the “Securities Act,” and Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the “Exchange Act,” that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement.

 

Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “targets,” “likely,” “will,” “would,” “could,” “should,” “continue,” “scheduled” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. Actual results, level of activity, performance, experience or achievements may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including risks and uncertainties relating, to:

 

our strategies, prospects, plans, expectations, forecasts or objectives;

 

our ability to achieve a marketable product (i.e., our insulin pump) and the costs and timing thereof;

 

acceptance of our product candidate by our target market and our ability to compete in such market;

 

our ability to raise additional financing when needed and the terms and timing thereof;

 

our ability to expand, protect and maintain our intellectual property rights;

 

our future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements, our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements;

 

our analysis of the target market for our insulin pump;

 

our ability to obtain all regulatory approvals and clearances relating to our insulin pump including those of the FDA;

 

regulatory developments in the United States and other countries;

 

the timing and costs of our obtaining all regulatory approvals and clearances identified immediately above;

 

our compliance with all applicable laws, rules and regulations, including those of the SEC and the FDA;

 

our ability to compete in the diabetes marketplace with larger and more substantial medical device companies;

 

general economic, business, political and social conditions;

 

S-4

 

 

our reliance on and our ability to retain (and if necessary, timely recruit and replace) our officers, directors and key employees and their ability to timely and competently perform at levels expected of them;

 

our ability to generate significant revenues and achieve profitability;

 

our ability to manage the growth of our business;

 

our commercialization, marketing and manufacturing capabilities and strategies;

 

our ability to expand, protect and maintain our intellectual property position;

 

the success of competing third-party products;

 

our ability to fully remediate our identified internal control material weaknesses;

 

our ability to meet the initial or continuing listing requirements of the Nasdaq Capital Market;

 

our ability to comply with regulatory requirements relating to our business, and the costs of compliance with those requirements, including those on data privacy and security;

 

the specific risk factors discussed under the heading “Risk Factors” set forth in this prospectus; and

 

various other matters, many of which are beyond our control.

 

S-5

 

 

USE OF PROCEEDS

 

We may issue and sell shares of our common stock having an aggregate sales proceeds of up to $6,500,000 from time to time. The amount of proceeds from this offering, if any, will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under, or fully utilize, the sales agreement with Leerink Partners as a source of financing.

 

We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including working capital, to fund our operations through the approval of our product by the FDA, expand our sales and marketing infrastructure, to fund additional research and development activities, to develop our initial manufacturing and production capabilities and make related capital expenditures. The amount and timing of these expenditures will depend on a number of factors, such as the timing, scope, progress and results of our research and development efforts.

 

As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering, if any. As a result, our management will have broad discretion regarding the timing and application of the net proceeds from this offering. Pending their use, we plan to invest the net proceeds from this offering in high-quality, short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.

 

S-6

 

 

DILUTION

 

If you invest in our common stock, you will experience dilution to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value as of September 30, 2023 was approximately $7.9 million or $0.38 per share of our common stock. Net tangible book value per share as of September 30, 2023 is equal to our total tangible assets minus total liabilities, all divided by the number of shares of common stock outstanding as of September 30, 2023.

 

After giving effect to the sale of approximately $6.5 million of shares of our common stock in this offering at an assumed offering price of $1.03 per share, the last reported sale price of our common stock on Nasdaq on November 21, 2023, and after deducting estimated offering commissions and expenses payable by us, our as adjusted net tangible book value would have been approximately $14 million or $0.51 per share of common stock, as of September 30, 2023. This represents an immediate increase in net tangible book value of approximately $0.13 per share to existing stockholders and an immediate dilution of approximately $0.52 per share to investors in this offering. The following table illustrates this calculation on a per share basis.

 

Assumed public offering price per share      $1.03 
Net tangible book value per share as of September 30, 2023  $0.38      
Increase in net tangible book value per share attributable to this offering  $0.13      
As adjusted net tangible book value per share as of September 30, 2023, after giving effect to this offering       $0.51 
Dilution per share to new investors purchasing shares in this offering       $0.52 

 

The table above assumes for illustrative purposes that an aggregate of 6,310,680 shares of our common stock are sold at a price of $1.03 per share, the last reported sale price of our common stock on Nasdaq on November 21, 2023, for aggregate gross proceeds of $6.5 million. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $1.03 per share shown in the table above, assuming $6.5 million of shares of our common stock is sold at that price, would increase our adjusted net tangible book value per share after the offering to $0.74 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $0.29 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $1.03 per share shown in the table above, assuming $6.5 million of shares of our common stock is sold at that price, would decrease our adjusted net tangible book value per share after the offering to $0.29 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $0.74 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only.

 

The number of shares of common stock shown above to be outstanding immediately following this offering is based on 21,123,726 shares outstanding as of September 30, 2023 excludes:

 

767,796 shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.00 per share;

 

5,449,478 shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.60 per share;

 

1,348,314 shares of our common stock issuable upon exercise of pre-funded warrants with an exercise price of $0.01 per share;

 

604,623 shares of our common stock issuable upon the exercise of warrants with an exercise price of $1.32 per share;

 

5,069,71shares of our common stock issuable upon the exercise of warrants with an exercise price of $1.22 per share;

 

2,912,664 shares of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately $4.54 per share;

 

229,166 shares of our common stock issuable upon vesting of restricted stock units; and

 

1,438,078 shares of our common stock reserved for issuance pursuant to future awards under our Amended and Restated 2017 Equity Incentive Plan, or the 2017 Plan.

 

S-7

 

 

PLAN OF DISTRIBUTION

 

We have entered into a sales agreement with Leerink Partners LLC (“Leerink Partners”) under which we may issue and sell from time to time up to $6,500,000 of our common stock through or to Leerink Partners as sales agent or principal. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act. If authorized by us in writing, Leerink Partners may purchase shares of our common stock as principal.

 

Leerink Partners will offer our common stock subject to the terms and conditions of the sales agreement as agreed upon by us and Leerink Partners. We will designate the maximum amount of common stock to be sold through Leerink Partners on a daily basis or otherwise determine such maximum amount together with Leerink Partners. Subject to the terms and conditions of the sales agreement, Leerink Partners will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct Leerink Partners not to sell common stock if the sales cannot be effected at or above the price designated by us in any such instruction. Leerink Partners or we may suspend the offering of our common stock being made through Leerink Partners under the sales agreement upon proper notice to the other party. Leerink Partners and we each have the right, by giving written notice as specified in the sales agreement, to terminate the sales agreement in each party’s discretion at any time.

 

The aggregate compensation payable to Leerink Partners as sales agent equal to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. We have also agreed to reimburse Leerink Partners up to $75,000 of Leerink Partners’s actual outside legal expenses incurred by Leerink Partners in connection with this offering plus certain ongoing fees of its legal counsel, plus an additional amount of up to $15,000 in connection with determining our compliance with the rules and regulations of the Financial Industry Regulatory Authority, Inc. (“FINRA”). We estimate that the total expenses of the offering payable by us, excluding commissions payable to Leerink Partners under the sales agreement, will be approximately $200,000.

 

The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock.

 

Leerink Partners will provide written confirmation to us following the close of trading on Nasdaq on each day in which common stock is sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading volume and the net proceeds to us.

 

To the extent any sales are made, we will report at least quarterly the number of shares of common stock sold through Leerink Partners under the sales agreement, the net proceeds to us and the compensation paid by us to Leerink Partners in connection with the sales of common stock.

 

Settlement for sales of common stock will occur, unless the parties agree otherwise, on the second business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

 

In connection with the sales of our common stock on our behalf, Leerink Partners will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation paid to Leerink Partners will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to Leerink Partners against certain liabilities, including liabilities under the Securities Act. As sales agent, Leerink Partners will not engage in any transactions that stabilizes our common stock.

 

Our common stock is listed on The Nasdaq Capital Market and trades under the symbol “MODD.” The transfer agent of our common stock is Colonial Stock Transfer Co., Inc.

 

Leerink Partners and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees.

 

In addition, in the ordinary course of its business activities, Leerink Partners and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. Leerink Partners and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

 

S-8

 

 

LEGAL MATTERS

 

Certain legal matters in connection with the securities offered hereby will be passed upon for us by Lucosky Brookman LLP. Leerink Partners is being represented in connection with this offering by Duane Morris LLP.

 

EXPERTS

 

Farber Hass Hurley LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2023, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Farber Hass Hurley LLP’s report, given on their authority as experts in accounting and auditing.

 

WHERE YOU CAN FIND MORE INFORMATION

 

We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the securities offered by this prospectus. This prospectus does not contain all of the information set forth in the registration statement, of which it is a part, and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC’s website at http://www.sec.gov.

 

We are subject to the information and periodic reporting requirements of the Exchange Act, and we file annual, quarterly and current reports, proxy statements and other documents with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC at http://www.sec.gov.

 

We also make these documents available on our website at www.modular-medical.com. Our website and the information contained or accessible through our website is not incorporated by reference in this prospectus, and you should not consider it part of this prospectus.

 

S-9

 

 

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

 

The SEC allows us to “incorporate” into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus is considered part of this prospectus.

 

Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. For more information, see “About this Prospectus.”

 

We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including any documents filed after the date on which the registration statement of which this prospectus is a part is initially filed until the offering of the security covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been “furnished” and not “filed” in accordance with SEC rules:

 

Our Annual Report on Form 10-K for the year ended March 31, 2023, filed with the SEC on June 26, 2023;

 

Our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 and September 30, 2023, filed with the SEC on August 14, 2023, and November 13, 2023, respectively;

 

Our Current Reports on Form 8-K, filed with the SEC on May 17, 2023, July 10, 2023 and October 5, 2023 (other than Exhibit 99.1); and

 

the description of our common stock contained in the Company’ Registration Statement on Form 8-A (File No. 001-41277) filed on February 9, 2022, including any amendment or report filed for the purpose of updating such description.

 

All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus and any previously filed documents.

 

Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

 

You can obtain any of the filings incorporated by reference into this prospectus through us or from the SEC through the SEC’s website at http://www.sec.gov. Upon request, we will provide, without charge, a copy of any or all of the reports and documents referred to above which have been incorporated by reference into this prospectus. Prospective investors may obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone from us at our executive offices at:

 

Modular Medical, Inc.

10740 Thornmint Road

San Diego, California 92127

(858) 800-3500

 

S-10

 

 

PROSPECTUS

 

 

MODULAR MEDICAL, INC.

$50,000,000

COMMON STOCK

PREFERRED STOCK

DEBT SECURITIES

WARRANTS

UNITS

 

This prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up to $50,000,000 of any combination of the securities described in this prospectus, either individually or in units. We may also offer common stock or preferred stock upon conversion of or exchange for the debt securities; and common stock or preferred stock or debt securities upon the exercise of warrants.

 

This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus supplement, carefully before you invest.

 

Our securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.

 

Our common stock is listed on the Nasdaq Capital Market, under the symbol “MODD.” On April 1, 2022, the last reported sale price of our common stock on the Nasdaq Capital Market was $4.25 per share.

 

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page 2 of this prospectus under the caption “Risk Factors.” We may include specific risk factors in supplements to this prospectus under the caption “Risk Factors.” This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is April 19, 2022

 

 

 

TABLE OF CONTENTS

 

  Page
   
ABOUT THIS PROSPECTUS ii
   
PROSPECTUS SUMMARY 1
   
RISK FACTORS 2
   
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3
   
USE OF PROCEEDS 4
   
GENERAL DESCRIPTION OF SECURITIES 5
   
DESCRIPTION OF CAPITAL STOCK 6
   
DESCRIPTION OF DEBT SECURITIES 7
   
DESCRIPTION OF WARRANTS 9
   
DESCRIPTION OF UNITS 10
   
PLAN OF DISTRIBUTION 10
   
LEGAL MATTERS 12
   
EXPERTS 12
   
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 13
   
WHERE YOU CAN FIND MORE INFORMATION 13

 

i

 

 

ABOUT THIS PROSPECTUS

 

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may offer shares of our common stock, preferred stock, various series of debt securities or warrants to purchase common stock or preferred stock, either individually or in units, in one or more offerings, with a total value of up to $50,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering.

 

This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. The prospectus supplement may also add, update or change information contained or incorporated by reference in this prospectus. However, no prospectus supplement will offer a security that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus supplements and the documents incorporated by reference into this prospectus, includes all material information relating to the offering of securities under this prospectus. You should carefully read this prospectus, the applicable prospectus supplement, the information and documents incorporated herein by reference and the additional information under the heading “Where You Can Find More Information” before making an investment decision.

 

You should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any prospectus supplement is accurate only as of the date on the front of the document and that any information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security.

 

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

 

This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control.

 

Unless the context otherwise requires, “Modular Medical,” “the Company,” “the Registrant,” “we,” “us,” “our” and similar terms refer to Modular Medical, Inc.

 

ii

 

 

PROSPECTUS SUMMARY

 

This summary highlights selected information that is presented in greater detail elsewhere in this prospectus or incorporated by reference in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities, and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus, the applicable prospectus supplement and any related free writing prospectus carefully, including the risks of investing in our securities discussed under the heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.

 

Overview

 

Modular Medical is a development stage medical device company focused on the design, development, and commercialization of an innovative insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product candidate seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets/

 

Our team has substantial knowledge of the diabetes industry and experience in developing, obtaining regulatory authorization for, and bringing insulin pumps to market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin, can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus (mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions.

 

Our goal is to become the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super users, but “diabetes care for the rest of us.”

 

The MODD1 is a high-precision, first-line pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to learn, easy to use, and has a revolutionary design and technology that enable precision with low-cost manufacture and high reproducibility.

 

Corporate Information

 

Our principal executive offices are located at 16772 West Bernardo Drive, San Diego, CA 92127 and our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com to which we regularly post copies of our press releases, as well as additional information about us. Our filings with the Securities and Exchange Commission, or SEC, will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained on, or accessible through, our website does not constitute a part of this prospectus or our other filings with the SEC, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our Units.

 

All brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties’ trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.

 

1

 

 

RISK FACTORS

 

Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the risk factors incorporated by reference to our Registration Statement on Form S-1, filed with the SEC on February 9, 2022, as amended, our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus, any accompanying prospectus supplement, and the documents incorporated by reference herein and therein, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this prospectus, any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, including statements regarding estimates, future events, our future financial performance, business strategy and plans and objectives of management for future operations, including with respect to us specifically and the cancer diagnostics industry in general, are forward-looking statements. We have attempted to identify estimates and forward-looking statements by terminology including “aims,” “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “plans,” “potential,” “predicts,” “seeks,” “should,” “suggests,” “targets” or “will” or the negative of these terms or other comparable terminology. Although we do not make estimates or forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Our estimates and forward-looking statements are based on our current assumptions and expectations about future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry’s actual results, levels of activity, performance or achievements to vary materially from those expressed or implied by these estimates and forward-looking statements.

 

Factors that could cause or contribute to such differences in results and outcomes include, but are not limited to, those discussed under the section entitled “Risk Factors” in this prospectus, any accompanying prospectus supplement, and in any documents incorporated by reference herein and therein. Readers should carefully review this information as well as other risks and uncertainties described in other filings with the SEC that we may make after the filing date of this prospectus. See the information included under the heading “Where You Can Find More Information.”

 

Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any estimates or forward-looking statements. All estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by applicable law or regulation, we undertake no obligation to update or to review any estimate and/or forward-looking statement. In light of these risks and uncertainties, we cannot assure you that the estimates or forward-looking statements contained in this prospectus, any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, will in fact occur. You should not place undue reliance on these estimates and forward-looking statements.

 

We qualify all of our forward-looking statements by these cautionary statements.

 

3

 

 

USE OF PROCEEDS

 

We intend to use the net proceeds we receive from the sale of our securities offered by us hereby for working capital and other general corporate purposes.

 

We may set forth additional information regarding the use of proceeds from the sale of securities we offer under this prospectus in a prospectus supplement relating to the specific offering. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of net proceeds.

 

4

 

 

GENERAL DESCRIPTION OF SECURITIES

 

We, directly or through agents, dealers or underwriters designated from time to time, may offer, issue and sell, together or separately, in one or more offerings, up to $50,000,000 in the aggregate, inclusive of any exercise price thereof, of:

 

  shares of our common stock, par value $0.001 per share;
     
  shares of our Preferred stock, par value $0.001 per share;
     
  debt securities;
     
  warrants to purchase shares of our common stock;
     
  units comprised of one or more shares of common stock and warrants in any combination; or
     
  any combination of the foregoing, each on terms to be determined at the time of sale.

 

The common stock, preferred stock, debt securities, warrants and units are collectively referred to herein as the securities. This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will, to the extent required by law, provide you with a prospectus supplement that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information in this prospectus. The securities involve various risks that we will describe in the section entitled “Risk Factors” that will be included in each prospectus supplement. For more details, see the information included under the heading “About this Prospectus.”

 

5

 

 

DESCRIPTION OF CAPITAL STOCK

 

We are authorized to issue up to 50,000,000 shares of Common Stock, par value $0.001 per share and up to 5,000,000 shares of preferred stock, par value $0.001 per share. As of April 1, 2022, we had 10,461,898 shares of our Common Stock outstanding.

 

The following description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to our amended and restated articles of incorporation, and our amended bylaws, each of which is incorporated herein by reference and are exhibits to the registration statement of which this prospectus forms a part. We encourage you to read our amended and restated articles of incorporation, our amended bylaws and the applicable provisions of the Nevada Revised Statutes (the “NRS”) for additional information.

 

Common Stock

 

Each holder of our Common Stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments. The holders of our Common Stock are entitled to one vote for each share or record on all matters to be voted on by our shareholders. There is no cumulative voting with respect to the election of our directors or any other matter. Therefore, under our charter documents, the holders of more than 50% of the shares voted for the election of those directors can elect all of the directors. Our board of directors currently are elected as a single class. Our board of directors may from time to time declare dividends on our outstanding shares. In the event of our liquidation, dissolution or winding up, the holders of our Common Stock are entitled to share ratably in all assets remaining available for distribution to them after payment of our liabilities and after provision has been made for each class of stock, if any, having any preference in relation to our Common Stock. Holders of shares of our Common Stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions applicable to our Common Stock.

 

Preferred Stock

 

Our articles of incorporation provide that our board of directors has the right in its discretion to issue preferred stock without approval of our shareholders and to set the series, classes, rights, privileges and preferences of our preferred stock or any classes, or series thereof without approval. In the event of a hostile takeover, the board of directors could potentially use this preferred stock to preserve control.

 

Outstanding Common Stock Warrants

 

As of April 1, 2022, we had the following warrants outstanding to purchase shares of our common stock:

 

  4,011,276 at an exercise price of $6.60 per share; and

 

  767,796 at an exercise price of $6.00 per share.

 

Outstanding Common Stock Options

 

As of April 1, 2022, we had 1,650,735 outstanding options to purchase shares of our Common Stock at a weighted average exercise price of $6.58 per share. In addition, on April 1, 2022, we had 989,435 shares available for future issuance under our Amended 2017 Equity Incentive Plan.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our Common Stock is Colonial Stock Transfer Company, Inc., 7840 S 700 E, Sandy, UT 84070. Its telephone number is 801-355-5740.

 

Stock Market Listing

 

Our common stock is listed on The Nasdaq Capital Market under the symbol “MODD.”

 

6

 

 

DESCRIPTION OF DEBT SECURITIES

 

The following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement shall control.

 

We may sell from time to time, in one or more offerings under this prospectus, debt securities, which may be senior or subordinated. We will issue any such senior debt securities under a senior indenture that we will enter into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture, which we will enter into with a trustee to be named in the subordinated indenture. We use the term “indentures” to refer to either the senior indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture Act of 1939, as in effect on the date of the indenture. We use the term “debenture trustee” to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.

 

The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all the provisions of the indenture applicable to a particular series of debt securities.

 

General

 

Each indenture will provide that debt securities may be issued from time to time in one or more series and may be denominated and payable in foreign currencies or units based on or relating to foreign currencies. Neither indenture will limit the amount of debt securities that may be issued thereunder, and each indenture will provide that the specific terms of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture, if any, relating to such series.

 

We will describe in each prospectus supplement the following terms relating to a series of debt securities:

 

    the title or designation;
     
  the aggregate principal amount and any limit on the amount that may be issued;
     
  the currency or units based on or relating to currencies in which debt securities of such series are denominated and the currency or units in which principal or interest or both will or may be payable;
     
  whether we will issue the series of debt securities in global form, the terms of any global securities and who the depositary will be;
     
  the maturity date and the date or dates on which principal will be payable;
     
  the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method for determining such dates;
     
  whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
     
  the terms of the subordination of any series of subordinated debt;
     
  the place or places where payments will be payable;

 

7

 

 

  our right, if any, to defer payment of interest and the maximum length of any such deferral period;
     
  the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional redemption provisions;
     
  the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities;
     
  whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves
     
  whether we will be restricted from incurring any additional indebtedness;
     
  a discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities;
     
  the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; and
     
  any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities.

 

We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.

 

Conversion or Exchange Rights

 

We will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.

 

Information Concerning the Debenture Trustee

 

The debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.

 

Payment and Paying Agents

 

Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.

 

We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check which we will mail to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the debenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.

 

8

 

 

All money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof.

 

Governing Law

 

The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.

 

Subordination of Subordinated Debt Securities

 

Our obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of senior indebtedness we may incur. It also does not limit us from issuing any other secured or unsecured debt.

 

DESCRIPTION OF WARRANTS

 

We may offer, sell and issue, from time to time, warrants to purchase shares of our common stock. The warrants may be issued independently or together with shares of our common stock and may be attached to or separate from the shares of our common stock. If we issue warrants, they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which will be contracts between us and/or a bank or trust company, as warrant agent, and the holders of the warrants or an agent for the holders of the warrants, all as shall be set forth in the prospectus supplement relating to warrants being offered pursuant to such prospectus supplement. The forms of warrant agreements or warrant certificates, as applicable, relating to the warrants will be filed as exhibits to the registration statement of which this prospectus is part and/or will be incorporated by reference from reports that we file with the SEC.

 

The following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all of the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.

 

Whenever warrants are to be issued and sold pursuant to this prospectus, we will file a prospectus supplement relating to that offer and sale which will specify (in each case as applicable):

 

    the number of shares of common stock purchasable upon exercise of the warrants and the exercise price at which such number of shares may be purchased upon exercise;
     
  the price or prices at which the warrants will be issued;
     
  the provisions, if any, for changes to or adjustments in the exercise price;
     
  the provisions, if any, for call rights or put rights relating to the warrants or the underlying shares of common stock;
     
  the date on which the right to exercise the warrants shall commence and the date on which the right will expire;
     
  if applicable, the number of warrants issued with each share of our common stock;
     
  if applicable, the date on and after which the warrants and the related common stock will be separately transferable; and
     
  any other terms of the warrants, including terms, procedures and limitations relating to the exchange, exercise and settlement of the warrants.

 

9

 

 

Until any warrants to purchase common stock are exercised, the holders of warrants will not be entitled, by virtue of being such holders, to vote, consent, receive dividends, receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter, or to exercise any rights whatsoever as our stockholders.

 

Each warrant will entitle the holder to purchase for cash such shares of our common stock at such exercise price as shall be in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the warrants offered thereby. Warrants may be exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void.

 

The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Upon receipt of payment and the warrant certificate properly completed and duly executed at the Company or the corporate trust office of the warrant agent, as applicable, or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the shares of our common stock purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.

 

DESCRIPTION OF UNITS

 

We may issue units comprised of one or more of the other securities described in this prospectus in any combination from time to time. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. If we issue units, they will be evidenced by unit agreements or unit certificates issued under one or more unit agreements, which will be contracts between us and the holders of the units or an agent for the holders of the units. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The forms of unit agreements or unit certificates, as applicable, relating to the units will be filed as exhibits to the registration statement that includes this prospectus, or as an exhibit to a filing with the SEC that is incorporated by reference into this prospectus.

 

PLAN OF DISTRIBUTION

 

We may sell our securities from time to time in any manner permitted by the Securities Act, including any one or more of the following ways:

 

    to investors through agents;
     
  directly to agents;
     
  to or through underwriters;
     
  to or through broker-dealers (acting as agent or principal);
     
  in a block trade;
     
  in ordinary brokerage transactions and transactions in which a broker solicits purchasers;
     
  in privately negotiated transactions;
     
  in “at the market” offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise; and/or
     
  directly to purchasers, through a specific bidding or auction process or otherwise.

 

The securities may be sold at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices relating to the prevailing market prices or at negotiated prices.

 

10

 

 

Offers to purchase offered securities may be solicited by agents designated by us from time to time. Any agent involved in the offer or sale of the offered securities in respect of which this prospectus is delivered will be named, and any commissions payable by us will be set forth, in the applicable prospectus supplement. Unless otherwise set forth in the applicable prospectus supplement, any agent will be acting on a reasonable best efforts basis for the period of its appointment. Any agent may be deemed to be an underwriter, as that term is defined in the Securities Act, of the offered securities so offered and sold.

 

We will set forth in a prospectus supplement the terms of the offering of our securities, including:

 

    the name or names of any agents, underwriters or dealers;
     
  the purchase price of our securities being offered and the proceeds we will receive from the sale;
     
  any over-allotment options under which underwriters may purchase additional securities from us;
     
  any agency fees or underwriting discounts and commissions and other items constituting agents’ or underwriters’ compensation;
     
  the public offering price;
     
  any discounts or concessions allowed or reallowed or paid to dealers; and
     
  any securities exchanges on which such securities may be listed.

 

If offered securities are sold to the public by means of an underwritten offering, either through underwriting syndicates represented by managing underwriters or directly by the managing underwriters, we will execute an underwriting agreement with an underwriter or underwriters, and the names of the specific managing underwriter or underwriters, as well as any other underwriters, will be set forth in the applicable prospectus supplement. In addition, the terms of the transaction, including commissions, discounts and any other compensation of the underwriters and dealers, if any, will be set forth in the applicable prospectus supplement, which prospectus supplement will be used by the underwriters to make resales of the offered securities. If underwriters are utilized in the sale of the offered securities, the offered securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including:

 

    transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded;
     
  in the over-the-counter market;
     
  in negotiated transactions; or
     
  under delayed delivery contracts or other contractual commitments.

 

We may grant to the underwriters options to purchase additional offered securities to cover over-allotments, if any, at the public offering price with additional underwriting discounts or commissions, as may be set forth in the applicable prospectus supplement. If we grant any over-allotment option, the terms of the over-allotment option will be set forth in the applicable prospectus supplement.

 

We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.

 

We may indemnify agents, underwriters and dealers against specified liabilities, including liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make in respect of such liabilities. Agents, underwriters or dealers, or their respective affiliates, may be customers of, engage in transactions with or perform services for us or our respective affiliates, in the ordinary course of business.

 

11

 

 

Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is traded on the Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange and, in the case of our common stock, on any additional exchange. However, unless otherwise specified in the applicable prospectus supplement, we will not be obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the offered securities.

 

Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

 

To comply with the securities laws of certain states, if applicable, the securities offered by this prospectus will be offered and sold in those states only through registered or licensed brokers or dealers.

 

In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement.

 

LEGAL MATTERS

 

Lucosky Brookman LLP will pass upon the validity of the issuance of the securities to be offered by this prospectus.

 

EXPERTS

 

Farber Hass Harley LLP, an independent registered public accounting firm, has audited our consolidated balance sheets as of March 31, 2021 and March 31, 2020, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the fiscal years then ended, which report is incorporated by reference in this prospectus. We have incorporated by reference our financial statements in this prospectus and in this registration statement in reliance on the report of Farber Hass Harley LLP given on their authority as experts in accounting and auditing.

 

12

 

 

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

 

The SEC allows us to “incorporate” into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus is considered part of this prospectus.

 

Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. For more information, see “About this Prospectus.”

 

We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including any documents filed after the date on which the registration statement of which this prospectus is a part is initially filed until the offering of the security covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been “furnished” and not “filed” in accordance with SEC rules:

 

    our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 filed with the SEC on June 29, 2021;
     
  our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2021, September 30, 2021 and December 31, 2021, filed with the SEC on August 16, 2021, November 12, 2021 and February 14, 2022, respectively;
     
  our Current Reports on Form 8-K filed with the SEC on May 12, 2021, May 24, 2021, August 16, 2021, September 17, 2021, September 30, 2021, October 29, 2021, December 1, 2021, December 3, 2021, January 4, 2022, February 14, 2022, and February 25, 2022; and
     
  the description of the Company’s Common Stock contained in the Company’ Registration Statement on Form 8-A (File No. 001-41277) filed on February 9, 2022, including any amendment or report filed for the purpose of updating such description.

 

We hereby undertake to provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into this prospectus. These documents are also available free of charge through the investors section on our website at www.modular-medical.com as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. You may request a copy of these filings, at no cost, by writing or telephoning us at the following:

 

Modular Medical, Inc.,

16772 W. Bernardo Drive

San Diego, CA 92127

Attention: Corporate Secretary

(858) 800-3500

 

You should rely only on the information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those respective dates.

 

WHERE YOU CAN FIND MORE INFORMATION

 

We file annual, quarterly and current reports and other information with the SEC. Our filings with the SEC are available from the SEC’s website at www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically.

 

This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is included in the registration statement. The registration statement contains more information regarding us and our securities, including certain exhibits. You can obtain a copy of the registration statement from the SEC’s website.

 

13

 

 

 

 

Up to $6,500,000

 

 

Common Stock

 

 

 

PROSPECTUS SUPPLEMENT

 

 

 

Leerink Partners

 

 

 

November 22, 2023

 

 

 

 

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg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image_003.jpg GRAPHIC begin 644 image_003.jpg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end